SCHEMBL1521627

SCHEMBL1521627

CSc1ncc2c(n1)N(C(C)C)C(=O)N(c1ccc(F)c(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c1)C2

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 6/20 0.40
BRAF P15056 6/20 0.39
TRPV1 Q8NER1 5/20 0.38
CDK8 P49336 2/20 0.37
CCNC P24863 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
RIPK2 O43353 1/20 0.37
ABCB11 O95342 1/20 0.37
ABL1 P00519 1/20 0.37
RAF1 P04049 1/20 0.37
NR3C1 P04150 1/20 0.37
RET P07949 1/20 0.37
HTR1A P08908 1/20 0.37
PDGFRB P09619 1/20 0.37
ADORA3 P0DMS8 1/20 0.37
KIT P10721 1/20 0.37
CHRM1 P11229 1/20 0.37
BCR P11274 1/20 0.37
FGFR1 P11362 1/20 0.37
RARG P13631 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1521409 0.91 FGFR4 (0.47) KDRBRAFTRPV1CDK8CCNC
SCHEMBL1521974 0.90 CDK8 (0.47) KDRBRAFTRPV1CDK8CCNC
SCHEMBL1521752 0.80 CDK8 (0.49) KDRBRAFTRPV1CDK8CCNC
SCHEMBL1521638 0.76 BRAF (0.47) KDRBRAFTRPV1CDK8HDAC6
SCHEMBL1521898 0.74 FGFR4 (0.35) KDRBRAFABL1RAF1FGFR1
SCHEMBL4284971 0.73 KDR (0.42) KDRBRAFTRPV1CDK8RIPK2
SCHEMBL5057707 0.71 KDR (0.44) KDRBRAFTRPV1ABL1PDGFRB
SCHEMBL1521748 0.70 RAB9A (0.43) KDRBRAFRAF1RETFLT3
SCHEMBL1521668 0.70 KDR (0.45) KDRBRAFRIPK2RAF1MAPK14
SCHEMBL1521536 0.70 KCNJ6 (0.47) BRAFRAF1MAPK11MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases FLYNN DANIEL L 2011-05-19 US disclosed
US-7897762-B2 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2011-03-01 US disclosed
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2009-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases BRAF, PRKDC, RAF1 KDR 500/4885BRAF 1/4885TRPV1 1959/4885
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases BRAF, PRKDC, RAF1 KDR 500/4885BRAF 1/4885TRPV1 1959/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.